A new clinical trial suggests that the drug daraxonrasib could significantly improve outcomes for patients with advanced pancreatic cancer. The trial involved 38 patients with KRAS-mutant pancreatic adenocarcinomas, who received a daily 300 milligram dose of daraxonrasib. Results indicated that the drug nearly doubled overall survival, extending it to an average of 15.6 months compared to the typical 6.7 months seen with standard chemotherapy. While some patients experienced manageable side effects like rash and fatigue, none discontinued treatment. Researchers believe daraxonrasib, a RAS inhibitor, has the potential to transform treatment for this disease, which is often diagnosed at late stages and has historically had very low survival rates. Further studies are ongoing to confirm these promising findings.